Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Harpoon Therapeutics (HARP – Research Report) on December 11. The company’s shares closed yesterday at $8.75. According to TipRanks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results